GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

Endometrial cancer starts in the tissue that lines your uterus. If the cancer is platinum-resistant, platinum-based chemotherapy drugs will not work well to kill it or stop it from returning after ...

The majority of women with uterine fibroids are asymptomatic, consequently get less clinical attention and fibroid tumors often remain undiagnosed. [23,24] Symptomatic women typically complain ...

Jan. 30, 2025 — A new study shows that artificial intelligence (AI) can help doctors make better decisions when treating cancer. However, it also highlights challenges in how doctors and AI work ...

You can’t pretend the pink pachyderm isn’t staring you in the face on Saturday. But if you must draw attention to it, at least soften the hard edges of your truth with graceful diplomacy. A ...

Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share ...

Self-sabotaging? You claim you want success but continue to shrink from the spotlight! It’s time to get comfortable with recognition. You hit a similar roadblock once and stopped when you should ...

Teva Pharmaceutical Industries Ltd. ADR-0.62% $20.28B ...